COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK

被引：0
作者：
Miller, B. [1 ]
Russel-Szymczyk, M. [2 ]
Jensen, I. S. [3 ]
Shah, A. [1 ]
Alexopoulos, S. T. [4 ]
Herbert, A. [4 ]
McLean, T. [4 ]
Tundia, N. [5 ]
机构：
[1] Precis Hlth Econ & Outcomes Res, Grafton, MA USA
[2] Merck Sp Zoo, Affiliate Merck KGaA, Warsaw, Poland
[3] Precis Hlth Econ & Outcomes Res, Boston, MA USA
[4] Merck Serono Ltd, Affiliate Merck KGaA, Feltham, England
[5] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE658
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
  • [11] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review
    Giovannoni, Gavin
    Mathews, Joela
    NEUROLOGY AND THERAPY, 2022, 11 (02) : 571 - 595
  • [12] Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study
    Inojosa, Hernan
    Schriefer, Dirk
    Ness, Nils-Henning
    Dillenseger, Anja
    Akguen, Katja
    Ziemssen, Tjalf
    JOURNAL OF NEUROLOGY, 2025, 272 (02)
  • [13] A BUDGET IMPACT ANALYSIS OF CLADRIBINE IN ENGLAND AND WALES FOR PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (HA-RRMS)
    Herbert, A.
    Ashton, L.
    Alexopoulos, S. T.
    VALUE IN HEALTH, 2023, 26 (12) : S119 - S119
  • [14] COST ANALYSIS OF SEVERAL TREATMENT SEQUENCES USED FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL: THE CASE FOR CLADRIBINE TABLETS
    Silverio, N.
    Goncalves, A.
    Fonseca, A.
    VALUE IN HEALTH, 2017, 20 (09) : A721 - A721
  • [15] Cladribine TabletsIn Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2011, 25 : 239 - 249
  • [16] Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensen, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP7
  • [17] Investigation of cladribine treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS) by means of modelling & simulation
    Terranova, N.
    Hicking, C.
    Dangond, F.
    Munafo, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 472 - 473
  • [18] An update on cladribine for relapsing-remitting multiple sclerosis
    Holmoy, Trygve
    Torkildsen, Oivind
    Myhr, Kjell-Morten
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1627 - 1635
  • [19] CLADRIBINE TABLETS (CT) VERSUS OTHER DISEASE-MODIFYING THERAPIES IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) - COST-EFFECTIVENESS ANALYSIS.
    Zieiba, P.
    Pawlik, D.
    Wieczorek, J.
    Wojcik, R.
    Kaczor, M. P.
    VALUE IN HEALTH, 2020, 23 : S632 - S632
  • [20] BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S205 - S205
12345